News Releases
Sep 5 2017
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Aug 11 2017
Peregrine Announces Measures to Reduce Costs, Facilitate Profitability and Strengthen its Operations
Jul 31 2017
Peregrine Provides Strategic Update
Jul 14 2017
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments
Jul 13 2017
Peregrine Pharmaceuticals Issues Statement Regarding Ronin Trading and SW Investment Management's Letter to Stockholders
Jul 7 2017
Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017
Jul 7 2017
Peregrine Pharmaceuticals Announces Reverse Stock Split
Jun 6 2017
Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock
Jun 5 2017
Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017
Apr 4 2017
Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy